Article Type
Editorial
Published
The Senior Editors of Drugs in Context are excited to announce that the journal received its first Impact Factor of 2.8 in the 2025 Edition of Journal Citation Reports by Clarivate.
Editorial
The Senior Editors of Drugs in Context are excited to announce that the journal received its first Impact Factor of 2.8 in the 2025 Edition of Journal Citation Reports by Clarivate.
Original Research
Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist indicated for treatment of chronic idiopathic constipation in adults. 5-HT4 receptors are present in the central nervous system; therefore, this article discusses non-clinical and clinical assessments evaluating the tissue distribution and abuse potential of prucalopride.
Review
This review article analyses the main pharmacokinetic aspects (ADME) that exist during the neonatal period and offers a description of the physiological background for variability in pharmacological dosing.